Pradeep Ramniklal Gosalia has sold 3,00,000 shares of Parmax Pharma Ltd, reducing his stake significantly from 8.09% to 0.07%. The transaction was done via a Share Purchase Agreement. This change in shareholding structure is a key disclosure for investors.
Parmax Pharma Ltd Shareholder Sells Over 99% Stake
Pradeep Ramniklal Gosalia has sold 3,00,000 shares of Parmax Pharma Ltd, reducing his stake to just 2,714 shares (0.07%). His pre-transaction holding was 3,02,714 shares, representing 8.09% of the company's equity. Reader Takeaway: Significant shareholding reduction by a major investor; no immediate impact on company operations. ## What just happened Shareholder Pradeep Ramniklal Gosalia has offloaded a substantial portion of his holdings in Parmax Pharma Ltd. He sold 3,00,000 shares on June 18, 2026, through a Share Purchase Agreement. This transaction drastically reduced his stake from 8.09% (3,02,714 shares) down to a mere 0.07% (2,714 shares). ## Why this matters This is a significant change in the ownership pattern of Parmax Pharma Ltd. A reduction of this magnitude by a shareholder who previously held over 8% signals a major shift. Investors closely watch such disclosures as they can sometimes precede other corporate actions or indicate a change in sentiment from a significant stakeholder. ## The backstory Prior to this transaction, Pradeep Ramniklal Gosalia was a notable shareholder in Parmax Pharma Ltd. The total equity share capital of the company stands at 37,41,300 shares, valued at ₹3.74 crore. ## What changes now The shareholding structure of Parmax Pharma Ltd has been altered due to this sale. The company's total equity remains unchanged, but the distribution among shareholders has shifted. The company's day-to-day operations and financial performance are not directly affected by this private share transfer. ## Risks to watch While this is a passive disclosure, a large stake sale could potentially create downward pressure on the stock price if the shares are sold in the open market subsequently or if it signals a loss of confidence. However, as the transaction was via a Share Purchase Agreement, it implies a private sale. ## Peer comparison Information on similar stake sales by major shareholders in comparable pharmaceutical companies is not available in the filing. ## Context metrics (time-bound) Transaction Date: June 18, 2026 Shares Sold: 3,00,000 Stake Reduction: 8.02% (from 8.09% to 0.07%) ## What to track next Investors should monitor future filings for any further changes in the shareholding pattern of Parmax Pharma Ltd, particularly concerning other major shareholders and promoters.
